Home > Insider Trading > Filing (0001209191-19-049105)

Filing Details

Accession Number:: 0001209191-19-049105
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-09-10 21:05:35
Reporting Period:: 2019-09-09

Accepted Time:: 2019-09-10 21:05:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1080709	Arena Pharmaceuticals Inc	ARNA	Pharmaceutical Preparations (2834)	232908305

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1657494	Vincent Aurentz	C/O Arena Pharmaceuticals, Inc. 6154 Nancy Ridge Drive San Diego CA 92121	Executive Vp And Cbo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-09-09	25,000	$17.10	25,000	No	4	M	Direct
Common Stock	Acquisiton	2019-09-09	10,000	$14.60	35,000	No	4	M	Direct
Common Stock	Acquisiton	2019-09-09	30,000	$35.60	65,000	No	4	M	Direct
Common Stock	Disposition	2019-09-09	44,672	$50.48	20,328	No	4	S	Direct
Common Stock	Disposition	2019-09-09	20,328	$51.23	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2019-09-09	25,000	$0.00	25,000	$17.10
Common Stock	Employee Stock Option (right to buy)	Disposition	2019-09-09	10,000	$0.00	10,000	$14.60
Common Stock	Employee Stock Option (right to buy)	Disposition	2019-09-09	30,000	$0.00	30,000	$35.60

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
55,000	2023-08-15	No	4	M	Direct
89,500	2024-02-13	No	4	M	Direct
100,000	2025-01-19	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.05 to $50.99, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes 2 and 3 to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.54, inclusive.
The options vest over four years and are exercisable once vested. 25% vested and became exercisable on August 15, 2017. The remainder of the options vest in thirty-six equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share), with the first installment vesting on September 15, 2017, and the thirty-sixth installment vesting on August 15, 2020.
The options vest over four years and are exercisable once vested. 25% vested and became exercisable on February 13, 2018. The remainder of the options vest in thirty-six equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share), with the first installment vesting on March 13, 2018, and the thirty-sixth installment vesting on February 13, 2021.
The options vest over four years and are exercisable once vested. 25% vested and became exercisable on January 19, 2019. The remainder of the options vest in thirty-six equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share), with the first installment vesting on February 19, 2019, and the thirty-sixth installment vesting on January 19, 2022.